Absolute Clinical Research, LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$29,200	2
2022	Research	$13,472	6
2021	Research	$14,300	2

Breakdown

Who paid Research payments · program years 2021–2025

AstraZeneca Pharmaceuticals LP $29,200 2 payments
Avanir Pharmaceuticals, Inc. $23,362 7 payments
Urovant Sciences Inc $4,410 1 payment

Studies the money was for Research payments · program years 2021–2025

17-Avp-786-205 $23,362 7 payments
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) $14,750 1 payment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event $14,450 1 payment
Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder $4,410 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.